{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:03:09Z","timestamp":1790787789220,"version":"4.1.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eisai Inc"},{"name":"Merck Sharp & Dohme Corp"},{"name":"Merck & Co"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for treating patients with locally recurrent or metastatic progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC). In this review, we discuss recent developments in the optimization of RR-DTC treatment with lenvatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Initiation of lenvatinib treatment before a worsening of Eastern Cooperative Oncology Group performance status and elevated neutrophil-to-lymphocyte ratio could benefit patients with progressive RR-DTC. The median duration of response with lenvatinib was inversely correlated with a smaller tumor burden, and prognosis was significantly worse in patients with a high tumor burden. An 18 mg\/day starting dose of lenvatinib was not noninferior to 24 mg\/day and had a comparable safety profile. Timely management of adverse events is crucial, as patients with shorter dose interruptions benefitted more from lenvatinib treatment. Caution should be exercised when initiating lenvatinib in patients who have tumor infiltration into the trachea or other organs, or certain histological subtypes of DTC, as these are risk factors for fistula formation or organ perforation. The Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT) eligibility criteria should be considered prior to initiating lenvatinib treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current evidence indicates that patients benefit most from lenvatinib treatment that is initiated earlier in advanced disease when the disease burden is low. A starting dose of lenvatinib 24 mg\/day, with dose modifications as required, yields better outcomes as compared to 18 mg\/day. Appropriate supportive care, including timely identification of adverse events, is essential to manage toxicities associated with lenvatinib, avoid longer dose interruptions, and maximize efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac065","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:15:51Z","timestamp":1648167351000},"page":"565-572","source":"Crossref","is-referenced-by-count":36,"title":["Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori J","family":"Wirth","sequence":"first","affiliation":[{"name":"Harvard Medical School, Massachusetts General Hospital , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1791-5915","authenticated-orcid":false,"given":"Cosimo","family":"Durante","sequence":"additional","affiliation":[{"name":"Sapienza University of Rome , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan J","family":"Topliss","sequence":"additional","affiliation":[{"name":"Alfred Health, and Monash University , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[{"name":"University of Western Ontario , London, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6268-4212","authenticated-orcid":false,"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[{"name":"Rabin Medical Center, Beilinson Hospital, Petach Tikva, Sackler Faculty of Medicine, Tel Aviv University , Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center , Asahi-ku, Yokohama, Kanagawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Luster","sequence":"additional","affiliation":[{"name":"University Hospital Marburg , Marburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5333-9257","authenticated-orcid":false,"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"University of Pisa , Lungarno Pacinotti, Pisa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Leboulleux","sequence":"additional","affiliation":[{"name":"Gustave-Roussy, Villejuif, France, and the University of Paris-Saclay , Gif-sur-Yvette , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East , Kashiwa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"2022070520465670400_CIT0001","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1001\/jamaoto.2014.1","article-title":"Current thyroid cancer trends in the United States","volume":"140","author":"Davies","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"2022070520465670400_CIT0002","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","article-title":"Lenvatinib: role in thyroid cancer and other solid tumors","volume":"42","author":"Cabanillas","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"2022070520465670400_CIT0003","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.otc.2010.01.002","article-title":"Evaluation of a thyroid nodule","volume":"43","author":"Bomeli","year":"2010","journal-title":"Otolaryngol Clin North Am."},{"key":"2022070520465670400_CIT0004","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol."},{"key":"2022070520465670400_CIT0005","doi-asserted-by":"crossref","first-page":"618985","DOI":"10.1155\/2012\/618985","article-title":"Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease","volume":"2012","author":"Busaidy","year":"2012","journal-title":"J Thyroid Res."},{"key":"2022070520465670400_CIT0006","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1186\/s12885-019-6369-7","article-title":"A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine","volume":"19","author":"Fleeman","year":"2019","journal-title":"BMC Cancer."},{"key":"2022070520465670400_CIT0007","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/1758834014548188","article-title":"Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer","volume":"6","author":"Worden","year":"2014","journal-title":"Ther Adv Med Oncol."},{"key":"2022070520465670400_CIT0008","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3390\/cancers11091382","article-title":"Radioiodine-refractory thyroid cancer: molecular basis of redifferentiation therapies, management, and novel therapies","volume":"11","author":"Aashiq","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2022070520465670400_CIT0009","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/a-1089-7870","article-title":"Updates on the management of thyroid cancer","volume":"52","author":"Araque","year":"2020","journal-title":"Horm Metab Res."},{"key":"2022070520465670400_CIT0010"},{"key":"2022070520465670400_CIT0011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet."},{"key":"2022070520465670400_CIT0012","volume-title":"Lenvima (lenvatinib) [prescribing information]","year":"2021"},{"key":"2022070520465670400_CIT0013","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med."},{"key":"2022070520465670400_CIT0014","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/ERC-18-0049","article-title":"Prolonged duration of response in lenvatinib responders with thyroid cancer","volume":"25","author":"Gianoukakis","year":"2018","journal-title":"Endocr Relat Cancer."},{"key":"2022070520465670400_CIT0015","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3389\/fendo.2019.00884","article-title":"Differentiated thyroid cancer, from active surveillance to advanced therapy: toward a personalized medicine","volume":"10","author":"Matrone","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2022070520465670400_CIT0016","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fendo.2017.00312","article-title":"Updates on the management of advanced, metastatic, and radioiodine refractory differentiated thyroid cancer","volume":"8","author":"Tumino","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2022070520465670400_CIT0017","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas","volume":"21","author":"Wassermann","year":"2016","journal-title":"Oncologist."},{"key":"2022070520465670400_CIT0018","first-page":"3","article-title":"Initial treatment of progressive differentiated thyroid cancer","volume":"14","author":"Tuttle","year":"2016","journal-title":"Clin Adv Hematol Oncol."},{"key":"2022070520465670400_CIT0019","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3390\/cancers13092279","article-title":"Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer","volume":"13","author":"Fukuda","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2022070520465670400_CIT0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"key":"2022070520465670400_CIT0021","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","journal-title":"Eur Thyroid J."},{"key":"2022070520465670400_CIT0022","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1507\/endocrj.EJ20-0025","article-title":"The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer","volume":"67","author":"Ito","year":"2020","journal-title":"Endocr J."},{"key":"2022070520465670400_CIT0023","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J Natl Cancer Inst."},{"key":"2022070520465670400_CIT0024","doi-asserted-by":"crossref","first-page":"98974","DOI":"10.18632\/oncotarget.21940","article-title":"Pretreatment nutritional risk scores and performance status are prognostic factors in esophageal cancer patients treated with definitive chemoradiotherapy","volume":"8","author":"Song","year":"2017","journal-title":"Oncotarget."},{"key":"2022070520465670400_CIT0025","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1002\/hed.25784","article-title":"Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer","volume":"41","author":"Suzuki","year":"2019","journal-title":"Head Neck."},{"key":"2022070520465670400_CIT0026","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1089\/thy.2020.0779","article-title":"Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib","volume":"31","author":"Taylor","year":"2021","journal-title":"Thyroid."},{"key":"2022070520465670400_CIT0027","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","article-title":"Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer","volume":"147","author":"Tahara","year":"2021","journal-title":"Eur J Cancer."},{"key":"2022070520465670400_CIT0028","article-title":"A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer","author":"Brose","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"key":"2022070520465670400_CIT0029","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2018.10.002","article-title":"Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer","volume":"106","author":"Tahara","year":"2019","journal-title":"Eur J Cancer."},{"key":"2022070520465670400_CIT0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00280-018-3687-4","article-title":"Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer","volume":"82","author":"Hayato","year":"2018","journal-title":"Cancer Chemother Pharmacol."},{"key":"2022070520465670400_CIT0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol."},{"key":"2022070520465670400_CIT0032","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/j.clon.2019.11.010","article-title":"Expert consensus on the management of adverse events during treatment with lenvatinib for thyroid cancer","volume":"32","author":"Reed","year":"2020","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2022070520465670400_CIT0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.beem.2017.04.012","article-title":"Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients","volume":"31","author":"Resteghini","year":"2017","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"key":"2022070520465670400_CIT0034","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/DDDT.S93459","article-title":"Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives","volume":"10","author":"Costa","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"2022070520465670400_CIT0035","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur Thyroid J."},{"key":"2022070520465670400_CIT0036","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1210\/jc.2015-4391","article-title":"Antiangiogenic tyrosine kinase inhibitors: occurrence and risk factors of hemoptysis in refractory thyroid cancer","volume":"101","author":"Lamartina","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2022070520465670400_CIT0037","first-page":"6438352","article-title":"A case of unresectable papillary thyroid carcinoma treated with lenvatinib as neoadjuvant chemotherapy","volume":"2020","author":"Iwasaki","year":"2020","journal-title":"Case Rep Endocrinol."},{"key":"2022070520465670400_CIT0038","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijscr.2017.10.010","article-title":"Surgical treatment of locally advanced papillary thyroid carcinoma after response to lenvatinib: A case report","volume":"41","author":"Tsuboi","year":"2017","journal-title":"Int J Surg Case Rep."},{"key":"2022070520465670400_CIT0039","doi-asserted-by":"crossref","first-page":"103186","DOI":"10.1016\/j.critrevonc.2020.103186","article-title":"Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis","volume":"157","author":"Das","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"key":"2022070520465670400_CIT0040","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of age on the efficacy and safety of lenvatinib in radioiodine-fefractory differentiated thyroid cancer in the phase III SELECT trial","volume":"35","author":"Brose","year":"2017","journal-title":"J Clin Oncol."},{"key":"2022070520465670400_CIT0041","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1089\/thy.2016.0549","article-title":"Defining radioiodine-refractory differentiated thyroid cancer: efficacy and safety of lenvatinib by radioiodine-refractory criteria in the SELECT trial","volume":"27","author":"Kiyota","year":"2017","journal-title":"Thyroid."},{"key":"2022070520465670400_CIT0042","doi-asserted-by":"crossref","first-page":"ix23","DOI":"10.1093\/annonc\/mdy430.001","article-title":"Relationships between lenvatinib plasma concentration and toxicity in Japanese cancer patients [abstract].","volume":"29","author":"Makihara","year":"2018","journal-title":"Ann Oncol"},{"key":"2022070520465670400_CIT0043","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin Pharmacol Ther."},{"key":"2022070520465670400_CIT0044","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1210\/js.2018-00241","article-title":"Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes","volume":"3","author":"Gomes-Lima","year":"2019","journal-title":"J Endocr Soc."},{"key":"2022070520465670400_CIT0045","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/thy.2013.0703","article-title":"Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma","volume":"24","author":"Liu","year":"2014","journal-title":"Thyroid."},{"key":"2022070520465670400_CIT0046","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40618-020-01374-7","article-title":"Bone metastases from differentiated thyroid carcinoma: current knowledge and open issues","volume":"44","author":"Nervo","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"2022070520465670400_CIT0047","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med."},{"key":"2022070520465670400_CIT0048","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/565\/44418256\/oyac065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/7\/565\/44418256\/oyac065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T16:47:46Z","timestamp":1657039666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/7\/565\/6575578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,4,28]]},"published-print":{"date-parts":[[2022,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac065","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742082082.793593142","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,4,28]]}}}